Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A

References

• SoucieJMEvattBJacksonDOccurrence of hemophilia in the United States. The Hemophilia Surveillance System Project InvestigatorsAm J Hematol1998592882949840909
   PubMed Web of Science ®Google Scholar
• Manco-JohnsonMJAbshireTCShapiroADProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophiliaN Engl J Med200735753554417687129
   PubMed Web of Science ®Google Scholar
• MinersAHSabinCATolleyKHAssessing health-related quality-of-life in individuals with haemophiliaHaemophilia1999537838510583523
   PubMed Web of Science ®Google Scholar
• RoyalSSchrammWBerntorpEQuality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patientsHaemophilia20028445011886464
   PubMed Web of Science ®Google Scholar
• ShapiroADDonfieldSMLynnHSDefining the impact of hemophilia: the Academic Achievement in Children with Hemophilia StudyPediatrics2001108E10511731632
   PubMed Web of Science ®Google Scholar
• GlobeDRCurtisRGKoerperMAUtilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS)Haemophilia200410Suppl1637014987251
   PubMed Web of Science ®Google Scholar
• SoucieJMNussREvattBMortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project InvestigatorsBlood20009643744210887103
   PubMed Web of Science ®Google Scholar
• PipeSConsideration in hemophilia therapy selectionSemin Hematol200643S232716631824
   PubMed Web of Science ®Google Scholar
• PipeSWRecombinant clotting factorsThromb Haemost20089984085018449413
   PubMed Web of Science ®Google Scholar
• ShapiroADKorth-BradleyJPoonMCUse of pharmacokinetics in the coagulation factor treatment of patients with haemophiliaHaemophilia20051157158216236106
   PubMed Web of Science ®Google Scholar
• BerntorpEBoulyjenkovVBrettlerDModern treatment of haemophiliaBull World Health Organ1995736917018846496
   PubMed Web of Science ®Google Scholar
• NilssonIMBerntorpELofqvistTTwenty-five years’ experience of prophylactic treatment in severe haemophilia A and BJ Intern Med199223225321640190
   PubMed Web of Science ®Google Scholar
• ShapiroADAnti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia AVasc Health Risk Manag2007355556518078007
   PubMedGoogle Scholar
• PanickerJWarrierIThomasRThe overall effectiveness of prophylaxis in severe haemophiliaHaemophilia2003927227812694517
   PubMed Web of Science ®Google Scholar
• ShapiroADA global view on prophylaxis: possibilities and consequencesHaemophilia20039Suppl 11017 discussion 1812709032
   PubMed Web of Science ®Google Scholar
• GouwSCvan der BomJGMarijke van den BergHTreatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort studyBlood20071094648465417289808
   PubMed Web of Science ®Google Scholar
• MolhoPRollandNLebrunTEpidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study [email protected]Haemophilia20006233210632738
   PubMed Web of Science ®Google Scholar
• Pneumocystis carinii pneumonia among persons with hemophilia AMMWR1982313653676815443
   PubMedGoogle Scholar
• Human immunodeficiency virus infection in the United States: a review of current knowledgeMMWR198736 Suppl 6148
   PubMedGoogle Scholar
• Committee to Study HIV Transmission Through Blood and Blood Products, Institute of MedicineHIV and the Blood Supply: An Analysis for Crisis DecisionmakingNational Academy PressWashington, DC1995
   Google Scholar
• KeshavjeeSWeiserSKleinmanAMedicine betrayed: hemophilia patients and HIV in the USSoc Sci Med2001531081109411556777
   PubMed Web of Science ®Google Scholar
• ChorbaTLHolmanRCClarkeMJEffects of HIV infection on age and cause of death for persons with hemophilia A in the United StatesAm J Hematol20016622924011279632
   PubMed Web of Science ®Google Scholar
• SoucieJMRichardsonLCEvattBLRisk factors for infection with HBV and HCV in a largecohort of hemophiliac malesTransfusion20014133834311274587
   PubMed Web of Science ®Google Scholar
• National Hemophilia Foundation. MASAC Document #151: MASAC recommendations concerning the treatment of hemophilia and other bleeding disorders. 2003.
   Google Scholar
• SoldanKDavisonKDowBEstimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003Euro Surveill200510171915735312
   PubMedGoogle Scholar
• PealerLNMarfinAAPetersenLRTransmission of West Nile virus through blood transfusion in the United States in 2002N Engl J Med20033491236124514500806
   PubMed Web of Science ®Google Scholar
• PedenAHHeadMWRitchieDLPreclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patientLancet200436452752915302196
   PubMed Web of Science ®Google Scholar
• DolanGClinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experienceHaemophilia200612Suppl 11620 discussion 26–1816445813
   PubMed Web of Science ®Google Scholar
• LlewelynCAHewittPEKnightRSPossible transmission of variant Creutzfeldt-Jakob disease by blood transfusionLancet200436341742114962520
   PubMed Web of Science ®Google Scholar
• TurnerMLLudlamCAAn update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma productsBr J Haematol2009144142318950452
   PubMed Web of Science ®Google Scholar
• AbeHSugawaraHHirayamaJRemoval of parvovirus B19 from hemoglobin solution by nanofiltrationArtif Cells Blood Substit Immobil Biotechnol20002837538311009110
   PubMed Web of Science ®Google Scholar
• ChandraSGroenerAFeldmanFEffectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived productsThromb Res200210539140012062540
   PubMed Web of Science ®Google Scholar
• KnightRSWillRGPrion diseasesJ Neurol Neurosurg Psychiatry200475 Suppl 1i36i4214978149
   PubMed Web of Science ®Google Scholar
• Eis-HubingerAMSasowskiUBrackmannHHParvovirus B19 DNA contamination in coagulation factor VIII productsThromb Haemost19998147647710102490
   PubMed Web of Science ®Google Scholar
• Eis-HubingerAMSasowskiUBrackmannHHParvovirus B19 DNA is frequently present in recombinant coagulation factor VIII productsThromb Haemost19967611208972042
   PubMed Web of Science ®Google Scholar
• SoucieJMSiwakEBHooperWCHuman parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitationTransfusion2004441179118515265122
   PubMed Web of Science ®Google Scholar
• Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disordersHaemophilia20039123
   PubMed Web of Science ®Google Scholar
• Association of Hemophilia Clinic Directors of CanadaClinical Practice Guidelines: Hemophilia and von Willebrand’s Disease (2. Management; Update 2)1999
   Google Scholar
• Centers for Disease ControlReport on the Universal Data Collection Program 2004
   Google Scholar
• EwensteinBMCollinsPTarantinoMDHemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free methodProceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and HaemostasisJuly 12 18, 2003Birmingham, UKSemin Hematol200441116 discussion 16–1815071785
   PubMedGoogle Scholar
• TarantinoMDCollinsPWHayCRClinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, nd safety in previously treated patients with haemophilia AHaemophilia20041042843715357767
   PubMed Web of Science ®Google Scholar
• BlanchetteVSShapiroADLiesnerRJPlasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patientsJ Thromb Haemost200861319132618503631
   PubMed Web of Science ®Google Scholar
• NegrierCShapiroABerntorpESurgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patientsThromb Haemost200810021722318690340
   PubMed Web of Science ®Google Scholar
• MantovaniLGMonziniMSMannucciPMDifferences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia: a discrete choice experimentHaemophilia20051158959716236108
   PubMed Web of Science ®Google Scholar
• WhiteGC2ndCourterSBrayGLA multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study GroupThromb Haemost1997776606679134639
   PubMed Web of Science ®Google Scholar
• AbshireTCBrackmannHHScharrerISucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy – International Kogenate-FS Study GroupThromb Haemost20008381181610896230
   PubMed Web of Science ®Google Scholar
• LusherJMLeeCAKesslerCMThe safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia AHaemophilia20039384912558777
   PubMed Web of Science ®Google Scholar
• BrayGLGompertsEDCourterSA multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study GroupBlood199483242824358167332
   PubMed Web of Science ®Google Scholar
• KreuzWGillJCRothschildCFull-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigationThromb Haemost20059345746715735795
   PubMed Web of Science ®Google Scholar
• WilsonKRickettsMNTransfusion transmission of vCJD: a crisis avoided?Lancet200436447747915302172
   PubMed Web of Science ®Google Scholar
• WhiteGC2ndRosendaalFAledortLMDefinitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and HaemostasisThromb Haemost20018556011307831
   PubMed Web of Science ®Google Scholar